PandaOmics

? The latest from PandaOmics! Introducing PandaOmics Box. Transform the #research landscape, empowering researchers to excel in target identification, biomarker discovery and indication prioritization. Hear from Insilico Medicine's CEO, Alex Zhavoronkov to learn more about this new #drugdiscovery toolkit. Visit our website today: https://lnkd.in/dsviKa7e

Dr. Petrina Kamya, Ph.D. joins the AI Summit Keynote speaker lineup, hosted by Boehringer Ingelheim, on Friday, November 22 in Ridgefield, CT! This first-ever event will converge AI thought leadership, showcase #innovation, and propel the State of Connecticut forward as a leader in #AI. Learn more about this new event here: https://lnkd.in/eEmzpfhk #AISummit #InsilicoMedicine #AISummitConnecticut

?? Beginning later this morning at 11:30 am EST! Pharma.AI Week kicks off with the PandaOmics and Science42: #DORA session. You will hear an overview of all new features now available on both platforms. Science42: DORA -Agentic Research -Web Search -Generation Transparency PandaOmics -Self Service Registration -Gene-disease association evidence from gene mutation data We hope to see you there! ?? https://lnkd.in/eH9pkfRV

? ? Have you registered for Pharma.AI Week yet? Beginning TOMORROW, the 3-day event will provide an exclusive look into the latest advancements and innovations within the?Pharma.AI?platform, which comprises Biology42, Chemistry42, Medicine42 and Science42. ?? We hope you and your colleagues will join us: https://lnkd.in/eH9pkfRV #Chemistry42 #PandaOmics #InsilicoWebinars #PharmaAI #PharmaAIWeek #DORA #TechWebinars #AI

?? Hot off the press from Fierce Biotech Insilico's AI-designed med tied to #respiratoryhealth improvements in midstage lung disease trial Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated improvements in a respiratory health measure for patients with idiopathic pulmonary fibrosis (#IPF). Read the full article here: https://lnkd.in/eds_UNXc #FierceBiotech #PhaseIIa #RespiratoryHealth

? Powered by Pharma.AI, Insilico has?nominated 20 preclinical candidates?in its comprehensive portfolio of over 30 assets since 2021 and has received IND approval for 9 molecules. AI software platforms used to discover TNIK and design ISM001-055,?Biology42: PandaOmics?and?Chemistry42: Generative Chemistry?are commercially available as part of Pharma.AI. Visit https://lnkd.in/eSq5CrqA for more information.

Dr. Petrina Kamya, Ph.D., joins the Industry Leading Speaker lineup at the #AIDrivenDrugDiscoverySummit in Boston! Petrina will be presenting "Case studies on leveraging AI from Target Discovery to the Clinic." Learn from real examples of where #AI has made a difference to the #drugdiscovery and development space. - Understand how and when AI was leveraged in the drug discovery value chain. At AIDD 2024, you can learn from industry leaders from Amgen, GSK, Novo Nordisk, Sanofi, Takeda and more about real-world successes and failures to avoid common pitfalls. #AIDD #BostonBiotech #GenerativeAI #AIConferences #AIDD2024

I am very happy to report the topline results from our double-blind placebo-controlled Phase IIa study in Idiopathic Pulmonary Fibrosis (IPF) which demonstrated unexpected dose-dependent efficacy - almost 100ml increase in Force Vital Capacity (FVC) at 60mg QD. For those of my friends who are not familiar with IPF, on standard of care FVC declines. It is very refreshing to see novel medicine discovered using generative AI where the target is novel and the molecule is novel to demonstrate this unprecedented result. We are now analyzing the multiomics data collected during the study and working on a publication to be submitted to the high peer-reviewed journal. We also think that selective TNIK inhibitors have absolutely massive indication expansion potential. Mark my words. I would like to thank all of my amzaing colleagues at Insilico Medicine, our investors who believed in us when we had nothing but the generative algorithms and some software, our contract research partners who worked day, night, weekend, and holiday, our advisors and academic partners. We are also very happy to have Dr. Carol Ann Satler, MD, PhD, FACC, FAHA, FAAP who has vast experience in IPF and other diseases join us to head all non-oncology clinical development to develop this program further. When you see this dose-dependent efficacy of this magnitude, you know that you need to do whatever it takes to get it to patients sooner - this is now our main objective. Please read the full story in the comments.

BREAKING: AI-driven drug shows promising Phase IIa results in treating fatal lung disease! Insilico Medicine just announced breakthrough results from its Phase IIa clinical trial for ISM001-055, an AI-designed drug candidate for idiopathic pulmonary fibrosis (IPF). This novel treatment could transform options for IPF, a disease with very few effective therapies available today. ?? Why This Matters IPF is a chronic, progressive lung disease that affects nearly 5 million people worldwide, with a median survival of only 3-4 years. Current treatments help slow disease progression but can’t stop or reverse it. Insilico’s ISM001-055 was developed using cutting-edge generative AI, targeting TNIK (Traf2- and NCK-interacting kinase), a key driver of lung fibrosis, to offer a potentially disease-modifying treatment. ?? Key Findings from Phase IIa ?? Trial Design: Double-blind, placebo-controlled study with 71 IPF patients across 21 sites in China. Patients were given one of three doses or a placebo over 12 weeks. ?? Lung Function Improvements: Patients on the highest dose (60 mg) showed a mean increase in forced vital capacity (FVC) of 98.4 mL, contrasting sharply with a mean decline of -62.3 mL in the placebo group. ?? Quality of Life Boost: The highest dose group also experienced a significant 2-point improvement on the Leicester Cough Questionnaire (LCQ), indicating better symptom control and quality of life. ?? Safety: ISM001-055 was well-tolerated, with only mild side effects reported, primarily gastrointestinal issues and minor liver function changes. ?? What’s Next? To build on these results, Insilico is now recruiting for a parallel Phase IIa trial in the United States to further validate the efficacy and safety of ISM001-055. If successful, this drug could shift the treatment paradigm for IPF. ?? Broader Impact Insilico Medicine’s PharmaAI platform seems to be a productive tool for designing first-in-class treatments faster (and arguably, quite efficiently, judring by ongoing clinical progress). Since 2021, Pharma.AI helped nominate over 20 preclinical candidates across a portfolio of more than 30 assets, with 9 molecules receiving IND approvals. ISM001-055, discovered and designed using @PharmaAI’s Biology42 (PandaOmics) and Chemistry42 modules, is the latest example of how AI can make impact on complex, life-threatening diseases like IPF. An important test for company's abilities will probably be next year when a landmark Phase III trima may launch. Full coverage on BioPharmaTrend.com (link in the comments). Image credit: Insilico Medicine

Join Jan Szollos, MBA, at the Eurosymposium on Healthy Aging in Brussels, on November 23. Jan will lead the "AI-Driven Data Analysis & Generative AI" presentation, which will feature the future of #longevity in research. There is still time to register in person and online here: https://bit.ly/3CmHmyh To meet with our team, please visit https://bit.ly/3UK7aux and contact our team today. #EuroSymposium #HealthyAgeing #HealthyLife